Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Thyroid cancer, drawn from the whole corpus: 40 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
3 medicines on record are linked to one of the types below rather than to Thyroid cancer itself. Grouped by the type that holds them; each list opens that type's own page.
Overdiagnosis of microcarcinoma.
Anaplastic thyroid cancer: BRAF V600E cases now respond to dabrafenib-trametinib, often enough to allow surgery; the 60% without the mutation still have few options.
Overdiagnosis: incidence has tripled with no change in mortality; most detected cancers would never have caused harm, yet surveillance uptake outside Japan and Korea remains low.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Anaplastic thyroid cancer without BRAF V600E (about 60%) still has a median survival of a few months.
Resistance to RET-selective inhibitors via solvent-front (G810) mutations has no approved next-generation drug.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Multikinase inhibitors for RAI-refractory disease cause hypertension, weight loss, and fatigue; most patients need dose reductions and quality of life suffers.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
No validated way to predict which low-risk patients will be the rare ones to recur, so follow-up intensity is uniform.
Also on OnCo: Find a trial · Expert centres.
Redifferentiation works in about half of refractory patients but predictors and optimal regimens are undefined.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Paediatric and radiation-induced thyroid cancers (Chernobyl, Fukushima cohorts) have distinct fusion-driven biology that is under-studied.
Hereditary MEN2 requires lifelong surveillance and prophylactic surgery in children; long-term outcomes of RET-selective therapy in this group are unknown.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 45 changes by month →When this page itself was last checked or edited.
Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.
A milestone in how this cancer is treated.
5-year recurrence-free ~98% (no RAI) vs ~96% (RAI).
A milestone in how this cancer is treated.
PFS HR 0.